Cladribine: Off-label disease modification for people with multiple sclerosis in resource-poor settings?

Zhifeng MaoCesar Alvarez-GonzalezStefania De TraneOzlem YildizChristo AlborGabriel DoctorDerek SoonGeorge PepperBenjamin P TurnerMonica MartaJoela MathewsGavin GiovannoniDavid BakerKlaus Schmierer

Published in: Multiple sclerosis journal - experimental, translational and clinical (2018)

Our viewpoint takes into account experience we have gathered over the past three years in the use of generic cladribine to treat pwMS. Whilst here we focus on MS, there is significant potential for use of cladribine in other conditions that could benefit from its mechanism of action.

Keyphrases

multiple sclerosis
mass spectrometry
white matter
ms ms
human health
risk assessment